1 ts for activity are, for the most part, very
intolerable.
2 disease-causing mutations are evolutionarily
intolerable.
3 -term and long-term side-effects that may be
intolerable.
4 east one of which included bexarotene unless
intolerable.
5 rogression was evident or toxic effects were
intolerable.
6 t they can escape if their suffering becomes
intolerable.
7 py is not sufficient for pain control or has
intolerable adverse effects or contraindications.
8 ]; n = 51) until disease progression, death,
intolerable adverse effects, or withdrawal of consent.
9 hine rotation included inadequate analgesia,
intolerable adverse effects, risky opioid regimens (eg,
10 , this treatment strategy is associated with
intolerable adverse effects.
11 kg, every 6 weeks until disease progression,
intolerable adverse events, or a maximum duration of 2 y
12 ess disease recurrence or new breast cancer,
intolerable adverse events, or consent withdrawal occurr
13 until disease progression, death, serious or
intolerable adverse events, study termination by sponsor
14 the time of disease progression or onset of
intolerable adverse events.
15 Cellular consequences of an
intolerable amount of change in the DNA structure are no
16 nfarction (MI) is frequently hemodynamically
intolerable and associated with multiple electrocardiogr
17 use by promoting the opinion that niacin is
intolerable and contraindicated in diabetes.
18 ted, the heat and particle fluxes may become
intolerable and damage the divertor.
19 oes brain ACh receptors, smoking would cause
intolerable and perhaps fatal muscle contractions.
20 5 oral formulation on the daily schedule was
intolerable at a dose and schedule explored.
21 oral drugs are ineffective, slow-acting, or
intolerable because of nausea and vomiting.
22 The
intolerable burden of malaria has for too long plagued h
23 patients for whom imatinib is ineffective or
intolerable,
but that could also be combined with the in
24 Side effects were described as
intolerable by 6 (8%) and their beta-blockers were stopp
25 ed that our screams were neither harmful nor
intolerable by presenting them at low intensity.
26 s mitigation gap, global warming may lead to
intolerable climate changes as adaptive capacity is exce
27 ld provoke an inflammatory response and thus
intolerable conditions for the cells.
28 earlier critical mechanical constraints and
intolerable dyspnea.
29 Intolerable exposure levels were not encountered.
30 pharmacotherapies for OUD are ineffective or
intolerable for many patients.
31 less than the release of source programs is
intolerable for results that depend on computation.
32 However, systemic reactions and
intolerable gastrointestinal AEs do occur and are signif
33 ions of mucosal integrity or, more commonly,
intolerable GI symptoms that may necessitate discontinua
34 s damage, the IOP was above 21 mmHg, or with
intolerable glaucoma medications.
35 o of four patients had DLTs (grade 3 nausea;
intolerable grade 2 fatigue).
36 ose-escalation phase (grade 3 acne [n=1] and
intolerable grade 2 mucosal inflammation [n=1]); hence,
37 nds upon tissue vulnerability, the number of
intolerable high-energy cycles applied in unit time (mec
38 (diarrhea, nausea, weight loss) that make it
intolerable in some patients.
39 response for the few whose suffering becomes
intolerable in spite of optimal palliative care.
40 These toxicities were
intolerable in two of six patients after receiving three
41 in the HypoPP trial was the occurrence of an
intolerable increase in attack severity or frequency (en
42 eases in mean blood pressure of > or =20% or
intolerable itching.
43 (11%) were removed from the study because of
intolerable joint pain.
44 ited replicative potential but also prevents
intolerable levels of chromosomal instability.
45 ivation of a p53-dependent checkpoint and/or
intolerable levels of genomic instability.
46 Loss of mitochondrial function generated
intolerable levels of reactive oxygen species (ROS), suf
47 utic efficacy and that targeting CDA induces
intolerable levels of replication stress in cancer cells
48 mutation rates in an adapting population to
intolerable levels.
49 ecting charges into the gain medium leads to
intolerable losses.
50 dynamics during the printing process lead to
intolerable microstructures with large columnar grains a
51 Intolerable mucosal toxicity occurred at higher doses of
52 Withdrawals because of
intolerable muscle symptoms were 18 participants (9%) du
53 topping chemotherapy in patients who develop
intolerable neuropathy and/or functional impairment.
54 c kinases exemplify this paradigm shift, but
intolerable on-target toxicities in more prolific normal
55 r differentiated myeloid cells, resulting in
intolerable on-target/off-tumour toxicity.
56 s refractory to opioid therapy or those with
intolerable opioid-related adverse effects.
57 lable for patients with trigeminal neuralgia
intolerable or resistant to medical therapy.
58 ecause of adverse events that made treatment
intolerable;
or treatment contraindicated or unsuitable
59 inical symptoms of endometriosis are chronic
intolerable pelvic pain and subfertility or infertility,
60 receptor essential volume (i.e., sterically
intolerable receptor regions).
61 applicability of highly potent but otherwise
intolerable regimens of cancer immunotherapy.
62 Limited efficacy and
intolerable safety limit therapeutic development and ide
63 Relapse, untreated psychosis,
intolerable side effects and the lack of effective treat
64 ir assigned treatment owing to inefficacy or
intolerable side effects or for other reasons.
65 The use of standard antibiotics may cause
intolerable side effects such as development of multidru
66 need to be applied in patients experiencing
intolerable side effects that they attribute to statins.
67 The times to discontinuation because of
intolerable side effects were similar among the groups,
68 scarring process but often at the expense of
intolerable side effects, and without substantially chan
69 s neuroprotective only at doses that produce
intolerable side effects, including memory impairment.
70 scontinuing treatment due to low efficacy or
intolerable side effects, it is important to explore alt
71 roleptics had been ineffective, had produced
intolerable side effects, or both.
72 for a sustainable therapeutic impact without
intolerable side effects, such as arrhythmia and tumour
73 owever, agents targeting VEGF are limited by
intolerable side effects, together with incomplete and t
74 t respond to current therapies or experience
intolerable side effects.
75 patients (9.7%) reported ineffectiveness or
intolerable side effects.
76 y abandoned because of a lack of efficacy or
intolerable side effects.
77 iscontinued treatment secondary to 1 or more
intolerable side effects.
78 tional chemotherapies cause many unwanted or
intolerable side effects.
79 doses (50 mg/day and 100 mg/day) resulted in
intolerable side effects.
80 at bimonthly intervals until progression or
intolerable side effects.
81 nadequate for certain types of pain or cause
intolerable side effects.
82 for 8 hours unless limited by hypotension or
intolerable side effects.
83 until disease progression or development of
intolerable side-effects.
84 teriorated with treatments, while others had
intolerable side-effects.
85 mg) or placebo until disease progression or
intolerable study drug-related toxicity.
86 ing, but there remain some patients for whom
intolerable suffering persists.
87 Patients who developed AI-associated
intolerable symptoms and discontinued treatment were giv
88 on abnormalities, hypotension, arrhythmia or
intolerable symptoms) was not reached at 3 min of the pe
89 However, for patients with
intolerable symptoms, therapeutic measures are warranted
90 erlying pathology and can be associated with
intolerable symptoms.
91 k capacity until they had to stop because of
intolerable symptoms.
92 ever, if the side-effects of anastrozole are
intolerable,
then switching to tamoxifen is a good alter
93 oxical in vitro activity, or that are highly
intolerable to changes.
94 On a scale of 0 (
intolerable)
to 10 (very tolerable) patients rated DPDT
95 ent is required until disease progression or
intolerable toxic effects occur.
96 eatment continued until disease progression,
intolerable toxic effects, or withdrawal of consent.
97 for 24 months or until disease progression,
intolerable toxic effects, withdrawal of consent, death,
98 mmended at lack of response or occurrence of
intolerable toxic effects.
99 every 6 weeks, until disease progression or
intolerable toxic effects.
100 t was continued until disease progression or
intolerable toxic effects.
101 until disease progression or development of
intolerable toxic effects.
102 of chemotherapy until disease progression or
intolerable toxic side-effects occurred.
103 ht combat leukemic growth while avoiding the
intolerable toxicities of NOTCH inhibitors.
104 DS-KS who experienced disease progression or
intolerable toxicities while receiving standard doxorubi
105 y was continued until disease progression or
intolerable toxicities.
106 FOLFIRI) plus cetuximab until progression or
intolerable toxicity (standard arm) or to FOLFIRI plus c
107 It is unknown whether patients with
intolerable toxicity from one AI are able to tolerate an
108 orinostat daily until disease progression or
intolerable toxicity in this open-label phase IIb trial
109 fications in the regimen should be done when
intolerable toxicity occurs or if viral load is increase
110 ot complete the planned treatment because of
intolerable toxicity or social problems.
111 cycles, until progressive disease, or until
intolerable toxicity resulted.
112 -2-weeks cycles until disease progression or
intolerable toxicity, included intravenous devimistat at
113 /kg every 3 weeks until disease progression,
intolerable toxicity, or consent withdrawal.
114 induction therapy until disease progression,
intolerable toxicity, or death.
115 3 weeks continued until disease progression,
intolerable toxicity, or investigator decision.
116 eatment continued until disease progression,
intolerable toxicity, or patient' s decision to disconti
117 0 mg/d or placebo until disease progression,
intolerable toxicity, or the end of 5 years.
118 D3 (n = 70) daily until disease progression,
intolerable toxicity, or withdrawal of consent.
119 e of 400 mg/m(2)) until disease progression,
intolerable toxicity, or withdrawal of consent.
120 ays for 24 weeks, until disease progression,
intolerable toxicity, or withdrawal of consent.
121 d study treatment until disease progression,
intolerable toxicity, withdrawal from the study, or stud
122 ks for up to 2 years or disease progression,
intolerable toxicity, withdrawal of consent, or investig
123 a 21-day cycle until disease progression or
intolerable toxicity.
124 us 21-day cycle until disease progression or
intolerable toxicity.
125 r 28-day cycles until disease progression or
intolerable toxicity.
126 mab maintenance until disease progression or
intolerable toxicity.
127 (weekly) in 28-day cycles until progression/
intolerable toxicity.
128 every 3 weeks, until disease progression or
intolerable toxicity.
129 Erlotinib was continued until progression or
intolerable toxicity.
130 tment continued until disease progression or
intolerable toxicity.
131 were treated until progression of disease or
intolerable toxicity.
132 gimen continued until disease progression or
intolerable toxicity.
133 ay continuously until disease progression or
intolerable toxicity.
134 described for unmappable or hemodynamically
intolerable VT.
135 An spt16 mutation was found to be
intolerable when combined with a mutation in any member
136 te approaches when imatinib is inadequate or
intolerable,
yet direct comparison in trials is lacking.